natgillin/translations-raw huggingface dataset:
The stimulation has the side effect of consuming honey and pollen by the bees, some bees' deaths, as well as looting from nearby beehives. 
Uzbuđivanje pčela ima nepoželjan učinak u tome što pčele troše med 1 pelud, neke pčele uginu, kao i u krađi iz susjednih košnica.
The method of claim 1, wherein the therapeutic cells comprise stem cells. The method of claim 1, further comprising applying the at least one therapeutic cell to the upper third of the mammal's nasal cavity in a physiologically effective amount to provide therapeutic action comprising replacement of lost and/or dying cells in the damaged central nervous system. 
Terapijske stanice namijenjene upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačene time što se navedeno liječenje dodatno sastoji u primjeni najmanje jedne terapijske stanice u gornju trećinu nosne šupljine životinje u fiziološki djelotvornoj količini kako bi se osiguralo terapijsko djelovanje, koje se sastoji u zamjeni izgubljenih i/ili umiručih stanica u oštećenom središnjom živčanom sustavu.
Others include EP 0 500 658, which describes a nicotine containing stimulant unit for buccal drug delivery, which can comprise a gum component and, as a sweetener, a sugar component and U.S. Pat. No. 6,183,775, which describes a controlled release lozenge comprising a soluble filler, an insoluble film-forming agent, and a swellable polymer. 
Drugi obuhvaćaju EP 0 500 658, koji opisuje stimulirajući! jedinicu za bukalnu primjenu lijeka koja sadrži nikotin, koja može sadržavati gumenu komponentu i, kao zaslađivač, šećernu komponentu i US 6,183,775, koji opisuje tabletu sa kontroliranim oslobađanjem koja sadrži topljivi punitelj, netopljivo sredstvo za formiranje filma, i polimer koji može bubriti.
an image located on a contact lens that a surgeon may reference to position the incision and the IOL; and/or a placement guide image combined or overlaid (44) with an image from a surgical microscope, within the lens removal console (42). 
Konzola za povlačenje leće prema zahtjevu 10, naznačena time, da je konzola za povlačenje leće (42) podešena da vizualno i/ili preko glasovne potvrde obavijesti kirurga o tome kuda da pomakne ili kako da okrene IOL.
The graphs reported in figures 1 and 2, evidence how the resin modified with'hexamine shows a much lower formaldehyde emission, not only with respect to the non modified resin as such, but also with respect to the resin additioned with urea before the preparation of the foam. 
Krive, prikazane na slici 1 i 2, pokažuju, kako ima smola, modificirana s heksaminom, vrlo malo emitiranje formaldehida, ne samo u usporedbi sa nemodificiranom smolom kao takovom, već i u usporedbi sa smolom, kojoj je dodan urin prije pripreme smole.
In one embodiment, at least about 20% to about 100% of the N-linked oligosaccharides in the Fc region of the glycoengineered antibody are nonfucosylated. 
Protutijelo u skladu sa zahtjevom 7, naznačeno time, da su najmanje 20% do 100% N-vezanih oligosaharida u Fc regiji nefukozilirani.
culturing the one or more cells in the copper supplemented cell culture media such that rVWF is expressed and excreted from the cells into a culture supernatant wherein the NH4+ content of the cell culture supernatant is maintained at a concentration below 4 mM; and recovering at least a portion of the culture supernatant, wherein the recovered supernatant has a rVWF specific ristocetin cofactor activity of at least 30 mU/µg rVWF. 
(d) uzgoja jedne ili više stanica u mediju za uzgoj stanica kompletiranom bakrom, tako da se rvWrF eksprimira i izlučuje iz stanica u supernatant kulture, gdje se sadržaj NHL* u supernatantu kulture stanica održava u koncentraciji ispod # mM; i (e) prikupljanja u najmanju ruku dijela supernatanta kulture, gdje prikupljeni supernatant ima aktivnost ristocetinskog sučimbenika specifičnu za rVWF od najmanje 30 mU/ug rVWF.
the poxvirus is selected from the group consisting of Modified Vaccinia Ankara (MVA) virus, Lister-Elstree vaccinia virus, LC16m8 vaccinia virus, CVI78 vaccinia virus, Fowl pox virus, canary pox virus, ALVAC, NYVAC, juncopox virus, mynah pox virus, pigeonpox virus, psittacine pox virus, quail pox virus, sparrow poxvirus, starling pox virus, and Turkey pox virus; 
- - pox virus ili rekombinantni pox virus izabran iz grupe koja obuhvaća Modificirani vakcinija Ankara (MVA) virus, Lister-Elstree vakcinija virus, LC16m8 vakcinija virus, CVI78 vakcinija virus, virus boginja peradi, virus boginja kanarinaca (tj. ALVAC), NYVAC, virus boginja ptice junko, virus boginja ptice mina, virus boginja goluba, virus boginja papiga, virus boginja prepelica, virus boginja vrabaca, virus boginja čvorka, virus boginja purana;
The method of claim 1, wherein the step of providing comprises providing at least 1000 L of a culture. 
Postupak prema Zahtjevu 1, naznačen time, što korak osiguravanja sadrži osiguravanje najmanje oko 1000 L kulture.
Clone 24 cells were cultured in Growth Medium (phenol red free Dulbecco's modified Eagle's medium (DMEM) containing 10% foetal bovine serum, 2 mM glutamine and 1.2 mg/ml G418) in a 7.5% CO2 air incubator at 37° C. Cells were harvested from T75 stock flasks by washing once in PBS (phosphate buffered saline, pH7.4, Gibco No. 
Stanice Klona 24 uzgojene su u hranjivom mediju (Dulbecco*'s modified Eagle's medium (DMEM), bez fenolnog crvenila, sa 10% fetalnog goveđeg seruma, 2 mM glutamina i 1.2 mg/ml G418) u zračnom inkubatoru sa 7.5% CO, pri temperaturi od 37 "C. Stanice se prikupe iz posuda za zalihe T75 jednokratnim ispiranjem sa PBS-om (fosfatom puferirana slana otopina (PBS), pH 7.4, Gibco No.
The terminal apparatus according to claim 3, wherein the determination section determines the amount of the resource QCW#0 + CW#1 shown in equation 1 using the multiplication result (Yoffset/rCW#0) obtained by multiplying the inverse of the coding rate rCW#0 by the correction factor Yoffset shown in equation 3, as the average of the inverses of the coding rates of the two code words: 
sekciju određivanja (204) koja određuje količinu resursa kontrolne informacije u pluralitetu slojeva; i sekciju prijenosa (206) koja prenosi kontrolnu informaciju na temelju količine resursa kontrolne informacije, naznačeno time da je količina resursa QCW#0+CW#1 kontrolne informacije određena jednadžbom 1:
and R7 together form a 1-2C-alkylenedioxy group, or a stereoisomer of the compound. 
R6 i R7 zajedno tvore 1-2C-alkilendioksi-skupinu, ili stereoizomer od toga spoja.
A vector comprising the nucleic acid molecule of claim 3. 
Vektor koji sadrži molekulu nukleinske kiseline prema patentnom zahtjevu 6, opcionalno naznačen time da;
The organic partition was evaporated to yield 650mg of crude compound but HPLC indicated that there was only approximately 20% product and mostly unreacted starting material; therefore, the reaction was restarted by repeating the above procedure and running the reaction for an additional six hours. 
Organski dio je bio isparen da bi se dobilo 650 mg sirovog spoja, ali HPLC je pokazao da je tamo bilo samo približno 20% produkta i neizreagiran početni materijal; stoga je reakcija ponovo započeta ponavljanjem gornjeg postupka i reakcija je bila provođena kroz dodatnih šest sati.
The salt according to claim 1, which salt is the benzene sulfonate salt of the compound of formula [I]. 
Sol u skladu s patentnim zahtjevom 1, naznačena time, što je to sol benzen-sulfata spoja formule [I].
The compound according to claim 1 having Formula (VI): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein: 
Spoj u skladu sa patentnim zahtjevom 1 koje ima Formulu (VI): ili njegov stereoizomer, tautomer, ili farmaceutski prihvatljiva sol, pri čemu:
or a tautomer, pharmaceutically acceptable salt, or solvate thereof, wherein: 
OH ili njegov tautomer, farmaceutski prihvatljiva sol, solvat ili klatrat, pri čemu:
The use according to any one of claims 18 to 25, wherein the pharmaceutical composition further comprises a thrombolytic agent, preferably a plasminogen activator, urokinase, streptokinase, alteplase or anistreplase. 
Upotreba prema bilo kojem zahtjevu 18 do 25, naznačena time, da farmaceutski sastav nadalje sadrži trombolitičko sredstvo, ponajprije aktivator plazminogena, urokinazu, streptokinazu, alteplazu ili anistreplazu.
In all the groups received AVP 60 min after the test drug. 
Sve skupine su primile AVP 60 min nakon ispitnog lijeka.
A compound of any one of aspects 1-32, or a pharmaceutically acceptable salt, hydrate, solvate or crystalline form thereof, for use in inhibiting growth of a cell transformed by a virus, wherein the virus is selected from the group consisting of human papilloma virus, HIV, hepatitis B virus, hepatitis C virus, variola virus, vaccinia virus, an adenovirus, a cytomegalovirus, herpes simplex virus 1, herpes simplex virus 2, Epstein Barr virus, BK virus, JC virus, feline leukemia virus and feline immunodeficiency virus. 
Spoj prema bilo kojem zahtjevu od 1 do 7, ili njegova farmaceutski prihvatljiva sol, za primjenu u inhibiciji rasta ćelija koje je transformirao virus, naznačen time, što je virus odabran 1z skupine koja se sastoji od ljudskog papilomavorusa, HIV-a, virusa hepatitisa B, virusa hepatitisa C, virusa boginja, virusa kravljih boginja, adenovirusa, citomegalovirusa, virusa herpesa simpleksa 1, virusa herpesa simpleksa 2, Epstein Barrovog virusa, BK virusa, JC virusa, cervikalne intraepitelne neoplazije, analne intraepitelne neoplazije i vulvarne intraepitelne neoplazije, virusa mačje leukemije i virusa mačje imunodeficijencije.
Water entering the capsule through the opening in the first wall is interacting with the ingredients contained in the capsule while traversing the interior of the capsule and is then made to leave the capsule through the opened outlet face. 
- - voda koja je ušla u čahuru kroz otvor na prvoj stijenki miješa se sa sastojcima koji su sadržani u čahuri dok prolazi kroz unutarnji dio čahure i tada napušta čahuru kroz otvor na izlaznoj plohi.
The electricity supply control system according to any one of claims 1 to 3, wherein said at least two electric meters are integrated in one single unit. 
Sustav za kontrolu električnog napajanja (100) u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time što su navedena najmanje dva brojila električne energije (103) integrirana u jednu zajedničku jedinicu.
The method of claim 10, wherein the unrearranged light chain variable region comprises a human Vk-Jk intergenic region from a human k light chain locus located downstream of the most 3′ hVλ gene segment and upstream of the most 5′ hJλ gene segment. 
HR P20190807 T1 lokusu održava element intronskog pojačivača K uzvodno od segmenta gena CK (označen kao EK1) i pojačivač 3' K nizvodno od segmenta gena CK (označen kao EK3').
A pharmaceutical composition, comprising a polynucleotide that encodes protein comprising amino acid sequence SEQ ID NO:1 or SEQ ID NO:2 in combination with a pharmaceutically acceptable carrier. 
Farmaceutski pripravak, naznačen time da sadrži polinukleotid koji kodira protein koji sadrži sekvencu aminokiseline SEQ ID NO:1 ili SEQ ID NO:2 u kombinaciji s farmaceutski prihvatljivim nosačem.
is H or alkyl; n is 1, 2 for 3; and A and B are fused to and form part of an unsubstituted or substituted monocyclic or polycyclic arene or heteroarene. 
RS je H ili alkuil; njel,2ili3;1 A 1B su kondenzirani na nesupstituirani ili supstituirani indol 1 tvore dio njega.
Use of an MMVF substrate according to any of claims 16 to 19, or an MMVF substrate formed from MMVF that has been made by a method according to any of claims 1 to 9, as (a) technical insulation or (b) fire protection at a temperature of at least 300ºC. 
Uporaba MMVEF supstrata sukladno bilo kojem od zahtjeva od 16 do 19, ili MMVF supstrat oblikovan od MMVF dobivenog postupkom sukladno bilo kojem zahtjevu od 1 do 9, naznačen time, što je kao (a) tehnička izolacija ili (b) zaštita od požara za temperature od najmanje 300 *€
Reaction progress was monitored by TLC and/or HPLC. 
Bio je praćen razvoj reakcije pomoću TLC 1ili HPLC.
a liquid aqueous pharmaceutical formulation comprising a therapeutically effective amount of Adalimumab in a buffered solution comprising L-Histidine and citrate, said formulation having a pH of 5 to 5.5 and having a content of aggregated species of Adalimumab after storage at 5°C for 3 to 6 months of less than 5 %; 
(a) tekuća vodena farmaceutska formulacija koja sadržava terapijski djelotvornu količinu Adalimumaba u puferiranoj otopini koja sadržava L-histidin i citrat, navedena formulacija ima pH od 5 do 5,5 i ima sadržaj agregiranih vrsta Adalimumaba, nakon skladištenja pri 5 *C tijekom 3 do 6 mjeseci, manje od 5 %;
The compound according to claim 8, wherein R3 is methyl. 
Tvar u skladu s patentnim zahtjevom 2, gdje je R3 metil.
Preparation of GnRH Radioligand 
Dobivanje radioliganda GnRH
The amorphous powder is then suspended in pure water, and the beaker containing the suspension is ultrasonicated for 12 hours to break the agglomerates in the powder. 
Amorfni prašak je zatim suspendiran u čistoj vod), a je čaša koja sadrži suspenziju ultrasonificirana kroz 12 sati da se razbiju aglomerati praška..
The method according to claim 1, wherein after the step of extruding the cooked slurry to form said meat substitute food product, the extruded meat substitute food product is further processed with water, salt, oil and spices and processed by a process selected from the group of processes consisting of brewing, hydrating, wetting and soaking for between 2-12 hours before performing an additional process step on said further processed meat substitute food product selected from the group of additional process steps consisting of baking, cooking and high pressure cooking. 
Postupak prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time što: nakon koraka ekstrudiranja kuhane kaše da nastane navedeni teksturirani prehrambeni proizvod, teksturirani prehrambeni proizvod se dalje obrađuje vodom, soli, uljem i začinima, te se vari, hidrira, vlaži ili namače prije provođenja dodatnog koraka pečenja, kuhanja ili kuhanja pod visokim pritiskom na navedenom daljnje obrađenom teksturiranom prehrambenom proizvodu. Postupak prema patentnom zahtjevu 5, naznačen time što se voda, ulje i začini raspršuju po teksturiranom prehrambenom proizvodu i posipava se sol.
The composition of claim 9, which is a pharmaceutical or a diagnostic composition. 
Sastav prema zahtjevu 10, naznačen time, da je to farmaceutski ili dijagnostički sastav.
In a sixth aspect of the first disclosure: 
Datum objave europskog patenta:
terminal sequence ID NO: 86) 
(86) Broj međunarodne prijave:
The composition according to claim 1, wherein component (A) is 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbornene-5-yl)amide. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1 Hpirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-iljamid, te kao komponentu (B) ciprodinil.
When treating for incontinence known methods and equipment require a visual survey meaning that the surgeon need to view an outflow of urine before knowing the right location to be treated in the bladder neck. 
Kada se liječi inkontinencija, poznati postupci i poznata oprema zahtijevaju vizualni pregled, znači da kirurg treba vidjeti istjecanje urina prije nalaženja pravog mjesta koje se treba liječiti na grliću mokraćnog mjehura.
the term "halogen" indicates a halogen atom selected from fluorine, chlorine, bromine or iodine; 
"halogen" jest atom halogena odabran od sljedećih: fluor, klor, brom te jod;
Use of a kit in a method for diagnosing colorectal cancer from a human feces sample according to claim 2, wherein said kit is characterized in that it comprises at least one pair of PCR primers selected from the group consisting of SEQ ID NO: 5-6, SEQ ID NO: 8-9 and SEQ ID NO: 11-12. 
Upotreba kompleta u skladu s patentnim zahtjevom 12, naznačena time što se navedene nukleinskokiselinske sonde u (1) ili par nukleinskokiselinskih početnica u (11) bira iz skupine koju čine SEQ ID NO: 2, SEQ ID NO: 13,
The composition of claim 11, wherein said composition is prepared by spray-drying. 
Sastav iz patentnog zahtjeva 11, pri čemu je navedeni sastav pripremljen sušenjem uz raspršivanje.
The fractions corresponding to the two peaks were subjected to hydrolysis to liberate the individual dihydrotetrabenazine isomers identified and characterised as Isomers A and B. Isomers A and B are each believed to have one of the following structures 
HR P20080677 T3 Frakcije koje su odgovarajuće za dva peak-a (vrha) se podvrgnu hidrolizi da bi se oslobodili pojedinačni izomeri dihidrotetrabenazina identificirani i okarakterizirani kao Izomeri A 1 B. Za Izomere A i B se smatra da imaju jednu od slijedećih struktura
The method of claim 18, wherein steps b) to d) are also carried out on the reverse side of the base layer to manufacture a print medium being coated on the first side and the reverse side. 
Postupak prema zahtjevu 17, naznačen time da se koraci b) do d) također provode na stražnjoj strani osnovnog sloja kako bi se proizvela tiskovna podloga koja je premazana na prvoj strani i stražnjoj strani.
Preferably, a BTDS contains buprenorphine in the form of a base or a salt, more preferably in the form of a base. 
Preferira se da TSB sadrži buprenorfin u obliku baze ili soli, više se preferira da je u obliku baze.
Q is N or CH; is hydrogen, CH3, CH2CH, or R1 and the carbon to which it is bound form a C═CH2 group; 
R' je vodik, CH, ili CH>CH,, ili R' i ugljik na kojeg je vezan tvore skupinu C=CH>;
One or more vector, particularly expression vector, comprising the polynucleotide(s) of claim 20. A host cell comprising the polynucleotide(s) of claim 20 or the vector(s) of claim 21. A method of producing a T cell activating bispecific antigen binding molecule according to claim 1 and capable of specific binding to CD3 and a target cell antigen, comprising the steps of a) culturing the host cell of claim 22 under conditions suitable for the expression of the T cell activating bispecific antigen binding molecule and b) recovering the T cell activating bispecific antigen binding molecule. 
Postupak proizvodnje bispecifične molekule vezane na antigen koji aktivira T stanicu u skladu s patentnim zahtjevom 1, i sposobne za specifično vezanje na CD3 i ciljni stanični antigen, naznačen time, da se sastoji od koraka a) kultivacije stanice domaćina prema patentnom zahtjevu 22 u uvjetima prikladnima za ekspresiju bispecifične molekule vezane na antigen koji aktivira T stanicu i b) oporavka bispecifične molekule vezane na antigen koji aktivira T stanicu.
—O—C1-6alkyl, which is unsubstituted or substituted with halogen, and 
(4) -O-Cisalkil, koji je nesupstituiran ili supstituiran sa halogenom, i
A compound represented by the formula (II): wherein R1 represents OR, NRR' which may form a ring, or SR, in which R and R' independently represent a hydrogen atom, a linear, cyclic or branched alkyl group having 1 to 8 carbon atoms optionally substituted with a one or a plurality of linear, cyclic or branched alkoxy groups having 1 to 8 carbon atoms, halogen atoms or hydroxyl groups, an aryl group optionally substituted with one or a plurality of linear, cyclic or branched alkyl groups having 1 to 8 carbon atoms, or linear, cyclic or branched alkoxy groups having 1 to 8 carbon atoms or halogen atoms, or a heteroaryl group optionally substituted with one or a plurality of linear, cyclic or branched alkyl groups having 1 to 8 carbon atoms, or linear, cyclic or branched alkoxy groups having 1 to 8 carbon atoms or a halogen atom, 
17. Spoj predstavljen formulom (II): pri čemu Ri predstavlja OR, NRR' koji može tvoriti prsten, ili SR, u kojem R i R' neovisno predstavljaju vodikov atom, ravnu, cikličku ili razgranatu alkilnu skupinu koja ima 1 do 8 ugljikovih atoma po izboru supstituiranu s jednom ili više ravnih, cikličkih ili razgranatih alkoksi skupina koje imaju 1 do 8 ugljikovih atoma, halogene atome ili hidroksilne skupine, arilnu skupinu po izoru supstituiranu s jednim ili više ravnih, cikličkih ili razgranatih alkilnih skupina koje imaju 1 do 8 ugljikovih atoma, ili ravna, ciklička ili razgranata alkoksi skupina koja ima 1 do 8 ugljikovih atoma ili halogene atome, ili heteroarilnu skupinu po izboru supstituiranu s jednim ili više ravnih, cikličkih 1li razgranatih alkil skupina koje imaju 1 do 8 ugljikovih atoma, ili ravna, ciklička ili razgranata alkoksi skupina koja ima 1 do 8 ugljikovih atoma ili halogeni atom,
The process according to claim 12, wherein the acid catalyst is alkylsulphonic acid bound to amorphous silica. 
Postupak prema patentnom zahtjevu 10, naznačeno time kiseli katalizator jest alkilsulfonska kiselina vezana na amorfni silicijev dioksid.
The composition or aerosol of any of claims 6 to 11, wherein the solution has a pH from about 4.5 to about 7.5, preferably from about 5 to about 6.5, more preferred from about 5.5 to about 6.5. 
Smjesa ili aerosol iz bilo kojeg od patentnih zahtjeva 6 do 11, pri čemu rastvor ima pH od oko 4,5 do oko 7,5, preporučljivo od oko 5 do oko 6,5, još preporučljivije od oko 5,5 do oko 6,5.
the antibody, or antigen binding portion thereof, that specifically binds to C . difficile toxin A comprises: a heavy chain variable region comprising one or more CDRs that are at least 80% identical to one or more of SEQ ID NOs:7 to 9 and a light chain variable region comprising one or more CDRs that are at least 80% identical to one or more of SEQ ID NOs: 16 to 18; 
Izolirano monoklonalno antitijelo ili njegov dio koji se veže za antigen, koji se specfično veže za i neutralizira Clostridium difficile (C. difficile) toksin A, pri čemu antitijelo, ili njegov dio koji se veže za antigen, je naznačeno time što sadrži: varijabilnu regiju teškog lanca koji sadrži CDR1, CDR2 i CDR3 aminokiselinske sekvence SEQ ID NOs: 7 do 9 i varijabilnu regiju lakog lanca koji sadrži CDR1, CDR2 i CDR3 sekvence SEQ ID NOs: 16 do 18;
A compound comprising a modified oligonucleotide having a nucleobase sequence consisting of any one of SEQ ID NO: 198, 228, 237, 440, 444, 448, 450, 453, 455, 549, and 598. 
Spoj koji obuhvaća modificiran oligonukleotid koji se sastoji od 20 vezanih nukleozida koji imaju nukleobaznu sekvencu koja obuhvaća sekvencu koja je navedena u SEQ ID NO: 440, 198, 228, 237, 444, 448, 450, 453, ili 455, 5
For example, a compound of the present invention or thereof and an insulin secretogogue such as biguanides, meglitinides, thiazolidinediones, sulfonylureas, insulin or a-glucosidose inhibitors can be administered to the patient together in a single oral dosage composition such as a tablet or capsule, or each agent administered in separate oral dosages. 
Kao primjer, spoj prema ovom izumu ili njegove soli, te inzulinski sekretagog, poput bigvanida, meglitinida, tiazolidindiona, sulfonilurea, inzulina ili inhibitora a-glukozidaze, može se primijeniti na pacijentu zajedno, u zajedničkom pripravku za oralno doziranje, poput tablete ili kapsule, ili se svako sredstvo primijenjuje u odvojenim oralnim doziranjima.
Compounds of the invention in optically pure form can be obtained from the corresponding racemates according to well-known procedures, e.g., HPLC with chiral matrix. 
Spojevi formula (1) i (Ia) u optički čistom obliku mogu se dobiti iz odgovarajućih racemata u skladu s dobro poznatim postupcima, npr. pomoću HPLC s kiralnom matricom.
A method of treating a damaging effect of ischemia on the central nervous system, comprising administering a PSD-95 inhibitor to a gyrencephalic primate having or at risk of ischemia, and performing reperfusion therapy on the primate, wherein the PSD-95 inhibitor and reperfusion treat a damaging effect of the ischemia on the central nervous system of the primate, and wherein the reperfusion therapy is performed more than 4.5 hours after onset of ischemia. 
Inhibitor PSD-95, namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačen time što se reperfuzijsku terapiju provodi više od 3 sata nakon početka ishemije, što se, izborno, reperfuzijsku terapiju provodi više od 4,5 sati nakon početka ishemije, ili što se reperfuzijsku terapiju provodi više od 4,5 sati, a manje od 24 sata nakon početka ishemije.